Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Carcinoma, Renal Cell
  • Immunosuppressive Agents
  • Kidney Neoplasms
  • Protein Kinase Inhibitors
  • Receptors, Vascular Endothelial Growth Factor
  • Sirolimus

abstract

  • Everolimus was associated with prolonged PFS relative to placebo in patients who received 1 or 2 previous VEGFr-TKIs. Patients who received only 1 previous VEGFr-TKI had apparently longer PFS with everolimus in reference to those who received 2 previous VEGFr-TKIs. These results support the use of everolimus as the standard of care in patients who fail initial VEGFr-TKI therapy.

publication date

  • February 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.ejca.2011.11.027

PubMed ID

  • 22209391

Additional Document Info

start page

  • 333

end page

  • 9

volume

  • 48

number

  • 3